Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18966688 | 0.81 | ANPEP (0.54) | CACNA1BCAPN1SCN9ACTSL | |
| SCHEMBL29740065 | 0.81 | CACNA1B (0.51) | CACNA1BBCHEMMP8CAPN1SCN9A | |
| SCHEMBL23961658 | 0.81 | CACNA1B (0.51) | CACNA1BBCHEMMP8CAPN1SCN9A | |
| SCHEMBL22622500 | 0.81 | CACNA1B (0.46) | CACNA1BBCHEMMP8CAPN1SCN9A | |
| SCHEMBL8956871 | 0.80 | CACNA1B (0.49) | CACNA1BBCHECAPN1SCN9ACTSL | |
| SCHEMBL19993350 | 0.79 | MMP8 (0.37) | CACNA1BBCHEMMP8ACHEEPHX1 | |
| SCHEMBL7439605 | 0.78 | CACNA1B (0.42) | CACNA1BBCHEMMP8CAPN1SCN9A | |
| SCHEMBL20542955 | 0.78 | LPAR3 (0.62) | MMP8CAPN1 | |
| SCHEMBL20543024 | 0.78 | LPAR3 (0.62) | MMP8CAPN1 | |
| SCHEMBL20543076 | 0.78 | LPAR3 (0.62) | MMP8CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022371-A1 | Compositions and methods for detecting and treating tumors containing acidic areas | SUMMERTON JAMES EDWARD (US) | 2012-01-26 | — | — | US | disclosed |
| US-8084610-B2 | Compositions and methods for detecting and treating tumors containing acidic areas | SUMMERTON JAMES EDWARD (US) | 2011-12-27 | — | — | US | disclosed |
| US-20080124274-A1 | Compositions and methods for detecting and treating tumors containing acidic areas | SUMMERTON JAMES EDWARD | 2008-05-29 | — | — | US | disclosed |
| US-20070286803-A1 | Compositions and methods for detecting and treating tumors containing acidic areas | SUMMERTON JAMES EDWARD | 2007-12-13 | — | — | US | disclosed |
| US-20070231256-A1 | Compositions and methods for detecting and treating tumors containing acidic areas | SUMMERTON JAMES E | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022371-A1 | Compositions and methods for detecting and treating tumors containing acidic areas | CA1, CA14, CA12 | CACNA1B 3581/4885BCHE 1640/4885MMP8 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.